NovoTect™ Bc diagnoses breast cancer based on the epigenetic targets associated with breast cancer in Asian women. NovoTect™ Bc is the first-ever test that stratifies patients regardless of sub-type and stage of breast cancer with high specificity and sensitivity.
Using just a simple blood sample, NovoTect™ Bc is a patient-friendly diagnostic option which allows physicians and patients to quickly and accurately reach a diagnosis while decreasing the rate of false-positives or identification of benign tumours associated with other diagnostic methods. This allows patients and physicians to identify the presence of disease and make important treatment decisions sooner.
Survival and successful treatment of breast cancer is strongly linked to the stage at which the disease is diagnosed. Over 90% of women diagnosed with breast cancer at the earliest stage survive their disease for at least 5 years, compared to approximately 15% for women diagnosed at an advanced stage of disease.1
How is NovoTect™ Bc Different to Current Screening Methods?
Mammography, an x-ray picture of breast tissue, is the standard diagnostic method for locating and diagnosing breast cancer. Dense breast tissue can cause mammograms to miss a breast cancer diagnosis. Dense breast tissue is twice as prevalent in women of Asian descent.
Many women seek additional genetic tests to determine their likelihood of developing breast cancer in their lifetime. Results from these tests can be confusing or lead to increased anxiety in women who test positive for the markers associated with breast cancer.
NovoTect™ Bc can be used alongside mammography to rapidly and accurately screen patients using a simple, low cost blood test. NovoTect™ Bc can be used for patients who are not yet receiving regular screenings; have presented with a false-positive result; or who have abnormal or difficult-to-interpret results from other diagnostic tools.
Nova Satra’s NovoTect Bc test offers a highly accurate, minimally invasive and convenient way to test patients for the presence of breast cancer. Accessible and affordable testing options can increase the screening participation rate, especially among women who are unwilling or unable to undergo other diagnostic tests that are more expensive or more invasive.